Loading
PTPRK (Receptor-type tyrosine-protein phosphatase kappa) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Bladder & urothelial cancer, Renal cell carcinoma and 5 more.
Regulation of processes involving cell contact and adhesion such as growth control, tumour invasion, and metastasis. Negative regulator of EGFR signalling pathway. Forms complexes with beta-catenin and gamma-catenin/plakoglobin.
Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes literature 0.93, animal model 0.59, genetic association 0.50, somatic mutation 0.85). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Bladder Urothelial Carcinoma, Renal Clear Cell Carcinoma, Non-Small Cell Lung Cancer.
In plain words · PTPRK (Receptor-type tyrosine-protein phosphatase kappa) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Bladder & urothelial cancer, Renal cell carcinoma and 5 more.
PTPRK (Receptor-type tyrosine-protein phosphatase kappa) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Bladder & urothelial cancer, Renal cell carcinoma and 5 more.
Regulation of processes involving cell contact and adhesion such as growth control, tumour invasion, and metastasis. Negative regulator of EGFR signalling pathway.
No product in this corpus aims at PTPRK yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
First described 1996. Earliest sequence paper UniProt cites for the protein: Fuchs et al, J. Biol. Chem, 1996, "Association of human protein-tyrosine phosphatase kappa with members of the armadillo family". Source.
Sources: HGNC HGNC:9674 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q15262 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000152894 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: colorectal cancer 0.55, melanoma 0.58, skin cancer 0.56, breast cancer 0.57 (GraphQL API, CC0)); IntOGen PTPRK (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Regulation of processes involving cell contact and adhesion such as growth control, tumour invasion, and metastasis. Negative regulator of EGFR signalling pathway. Forms complexes with beta-catenin and gamma-catenin/plakoglobin. Beta-catenin may be a substrate for the catalytic activity of PTPRK/PTP-kappa. Location: Cell junction, adherens junction; Cell membrane (UniProt). Locus 6q22.33 (HGNC).
Query for this target: (TITLE:"PTPRK" OR ABSTRACT:"PTPRK" OR TITLE:"protein tyrosine phosphatase receptor type K" OR ABSTRACT:"protein tyrosine phosphatase receptor type K" OR TITLE:"Receptor-type tyrosine-protein phosphatase kappa" OR ABSTRACT:"Receptor-type tyrosine-protein phosphatase kappa" OR TITLE:"R-PTP-kappa" OR ABSTRACT:"R-PTP-kappa") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTPRK, not a curated reading list.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Bladder & urothelial cancer, IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Breast cancer (all types).
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen.